Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
9.78
-1.13 (-10.36%)
At close: Oct 13, 2026, 4:00 PM EDT
9.73
-0.05 (-0.51%)
After-hours: Oct 13, 2026, 5:26 PM EDT
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
612.05M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| MiMedx Group | 355.17M |
| Zevra Therapeutics | 136.07M |
| 4D Molecular Therapeutics | 92.01M |
| Lexicon Pharmaceuticals | 41.47M |
| OmniAb | 38.46M |
| Attovia Therapeutics | 1.80M |
| Avalo Therapeutics | 59.00K |
DSGN News
- 11 days ago - Design Therapeutics initiated with an Overweight at Wells Fargo - TheFly
- 4 weeks ago - Design Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - Design Therapeutics management to meet with Oppenheimer - TheFly
- 5 weeks ago - Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Design Therapeutics reports Q2 EPS (32c), consensus (34c) - TheFly
- 2 months ago - Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - Design Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Design Therapeutics Earnings release: Q2 2026 - Filings